Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

    Supports laboratory optimization and clinical validation of cancer biomarkers and assays using human samples to address defined clinical needs; clinical trials are not allowed.

    Browse similar grants
    Cancer Research Grants 2026
    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: National Institutes of Health

    Due Dates: February 16, 2027 (New) | March 16, 2027 (Resubmission) | June 16, 2027 (New) | July 16, 2027 (Resubmission) | October 16, 2027 (New) | November 16, 2027 (Resubmission) | February 16, 2028 (New) | March 16, 2028 (Resubmission) | June 16, 2028 (New) | July 16, 2028 (Resubmission) | October 16, 2028 (New) | November 16, 2028 (Resubmission) | February 16, 2029 (New) | March 16, 2029 (Resubmission) | June 16, 2029 (New) | July 16, 2029 (Resubmission) | October 16, 2029 (New) | November 16, 2029 (Resubmission; final closing)

    Funding Amounts: UH2: up to $275,000 direct costs over two years ($200,000 annual cap); UH3: up to $250,000 direct costs annually for three years

    Summary: Supports analytical and clinical validation of existing human-sample biomarker assays for clearly defined cancer-related clinical uses.

    Key Information: Clinical trials, biomarker discovery, and early-stage assay technology development are not supported.


    Description

    The National Cancer Institute (NCI), part of NIH, supports validation of molecular, cellular, and in vitro imaging biomarkers through this cooperative agreement. Eligible work addresses cancer detection, diagnosis, prognosis, monitoring, treatment response or resistance, prevention and control, pharmacodynamics, or toxicity. Projects must optimize existing assays already demonstrated in human specimens for a well-defined clinical context, rather than discover biomarkers or develop early-stage technologies.

    Applicants may pursue phased analytical and clinical validation through UH2/UH3, or clinical validation of an analytically validated assay through a standalone UH3. Multicenter harmonization and reproducibility studies are also appropriate, and AI-driven biomarkers are included. Imaging means microscopy and other in vitro modalities, not clinical radiology. NCI staff actively assist with scientific, analytical, clinical, and regulatory issues to help prepare assays for future cancer trials or studies.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.